Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

被引：0
|
作者：
Offidani, Massimo
Corvatta, Laura
Maracci, Laura
Liberati, Anna Marina
Ballanti, Stelvio
Attolico, Immacolata
Caraffa, Patrizia
Alesiani, Francesco
di Toritto, Tommaso Caravita
Gentili, Silvia
Tosi, Patrizia
Brunori, Marino
Derudas, Daniele
Ledda, Antonio
Gozzetti, Alessandro
Cellini, Claudia
Malerba, Lara
Mele, Anna
Andriani, Alessandro
Galimberti, Sara
Mondello, Patrizia
Pulini, Stefano
Coppetelli, Ugo
Fraticelli, Paolo
Olivieri, Attilio
Leoni, Pietro
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1974.1974
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1974
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PEGFILGRASTIM VERSUS FILGRASTIM IN THE MANAGEMENT OF POST-CHEMOTHERAPY NEUTROPENIA IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN TREATMENT WITH BVD (BENDAMUSTINE BORTEZOMIB-DEXAMETHASONE)
    Cerchione, C.
    Nappi, D.
    Salvatore, D.
    Migliaccio, I.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2016, 101 : 550 - 551
  • [42] Bendamustine-Bortezomib-Desametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma : A REAL-Life Experience
    Cerchione, Claudio
    Catalano, Lucio
    Pareto, Anna Emanuele
    Basile, Santina
    Marano, Luana
    Peluso, Ilaria
    Simeone, Luigia
    Vitagliano, Orsola
    Palmieri, Salvatore
    Rocco, Stefano
    Ferrara, Felicetto
    Pane, Fabrizio
    BLOOD, 2015, 126 (23)
  • [43] BORTEZOMIB PLUS DEXAMETHASONE IN COMBINATION WITH MELPHALAN OR CYCLOPHOSPHAMIDE IN THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Tsirigotis, P.
    Girkas, K. G.
    Giannopoulou, V.
    Chondropoulos, S.
    Ioannidou, E.
    Papaxoinis, G.
    Pappa, V.
    Vasilatou, D.
    Dimoula, K.
    Kapodistrias, N.
    Papageorgiou, E.
    Economopoulos, T.
    Dervenoulas, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 436 - 436
  • [44] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Shinsuke Iida
    Tatsuo Ichinohe
    Atsushi Shinagawa
    Kenshi Suzuki
    Naoki Takezako
    Masayuki Aoki
    International Journal of Hematology, 2018, 107 : 460 - 467
  • [45] Bendamustine-Bortezomib-Desametasone (BVD) in the Management of Relapsed and Refractory Multiple Myeloma : A REAL-Life Experience
    Cerchione, Claudio
    Catalano, Lucio
    Pareto, Anna Emanuele
    Basile, Santina
    Marano, Luana
    Peluso, Ilaria
    Simeone, Luigia
    Vitagliano, Orsola
    Nappi, Davide
    Palmieri, Salvatore
    Rocco, Stefano
    Ferrara, Felicetto
    Pane, Fabrizio
    BLOOD, 2016, 128 (22)
  • [46] A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Hajek, Roman
    Pour, Ludek
    Ozcan, Muhit
    Sanchez, Jesus Martin
    Sanz, Ramon Garcia
    Anagnostopoulos, Achilles
    Oriol, Albert
    Cascavilla, Nicola
    Terjung, Andreas
    Lee, Yihua
    Briso, Eva M.
    Dobkowska, Edyta
    Hauns, Bernhard
    Spicka, Ivan
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (05) : 435 - 442
  • [47] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Ichinohe, Tatsuo
    Shinagawa, Atsushi
    Suzuki, Kenshi
    Takezako, Naoki
    Aoki, Masayuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (04) : 460 - 467
  • [48] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Victoria Mateos, Maria
    Prosper, Felipe
    Martin Sanchez, Jesus
    Ocio, Enrique M.
    Oriol, Albert
    Motllo, Cristina
    Michot, Jean-Marie
    Jarque, Isidro
    Iglesias, Rebeca
    Sole, Maria
    Martinez, Sara
    Kahatt, Carmen
    Fudio, Salvador
    Corral, Gema
    Zeaiter, Ali
    Montilla, Lola
    Ribrag, Vincent
    CANCER MEDICINE, 2023, 12 (04): : 3999 - 4009
  • [49] PANOBINOSTATPK/PD IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITHRELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
    Mu, S.
    Tajima, T.
    Corrado, C.
    Sunami, K.
    Suzuki, K.
    Hino, M.
    Kuroda, Y.
    Shibayama, H.
    Lin, R.
    Waldron, E.
    Binlich, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S49 - S49
  • [50] BENDAMUSTINE-BORTEZOMIB-DESAMETASONE (BVD) IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REAL-LIFE EXPERIENCE
    Cerchione, C.
    Catalano, L.
    Pareto, A. E.
    Basile, S.
    Marano, L.
    Peluso, I.
    Simeone, L.
    Vitagliano, O.
    Palmieri, S.
    Ferrara, F.
    Pane, F.
    HAEMATOLOGICA, 2016, 101 : 792 - 792
12345